{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on the Omission of Tamponade Dressings after Haemorrhoidectomy"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "Conducted as an open-label, multicentre randomised controlled trial in 14 German hospitals"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients with grade III or IV haemorrhoids"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised 1:1 to either no tamponade (intervention) or tamponade (control) groups"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to determine if omitting tamponade dressings after haemorrhoidectomy reduces postoperative pain without increasing severe bleeding risk."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcomes were maximum pain intensity within 48 hours post-surgery (superiority) and severe bleeding requiring surgical re-intervention within 7 days (non-inferiority)."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was centre-stratified with variable block sizes, and allocation was concealed via a web-based tool."
      },
      "Blinding": {
        "score": 0,
        "evidence": "No blinding was implemented."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "From May 2017 to November 2020, 754 patients were randomised (366 intervention, 359 control)."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "366 intervention, 359 control"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The intervention group reported lower median pain intensity (5, i.q.r. 3\u20137) compared to the control group (6, i.q.r. 4\u20137), P < 0.001. Severe bleeding occurred in 1.1% of patients in both groups, with a non-inferiority margin of \u22120.03% (90% CI \u22121.47% to +1.41%)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar between groups."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: DRKS00011590."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 20,
    "max_score": 25
  },
  "model": "gpt-4o"
}